Recommended Approaches to Minimize Aerosol Dispersion of SARS-CoV-2 During Noninvasive Ventilatory Support Can Cause Ventilator Performance Deterioration: A Benchmark Comparative Study.


Journal

Chest
ISSN: 1931-3543
Titre abrégé: Chest
Pays: United States
ID NLM: 0231335

Informations de publication

Date de publication:
07 2021
Historique:
received: 30 11 2020
revised: 28 01 2021
accepted: 18 02 2021
pubmed: 6 3 2021
medline: 21 7 2021
entrez: 5 3 2021
Statut: ppublish

Résumé

SARS-CoV-2 aerosolization during noninvasive positive-pressure ventilation may endanger health care professionals. Various circuit setups have been described to reduce virus aerosolization. However, these setups may alter ventilator performance. What are the consequences of the various suggested circuit setups on ventilator efficacy during CPAP and noninvasive ventilation (NIV)? Eight circuit setups were evaluated on a bench test model that consisted of a three-dimensional printed head and an artificial lung. Setups included a dual-limb circuit with an oronasal mask, a dual-limb circuit with a helmet interface, a single-limb circuit with a passive exhalation valve, three single-limb circuits with custom-made additional leaks, and two single-limb circuits with active exhalation valves. All setups were evaluated during NIV and CPAP. The following variables were recorded: the inspiratory flow preceding triggering of the ventilator, the inspiratory effort required to trigger the ventilator, the triggering delay, the maximal inspiratory pressure delivered by the ventilator, the tidal volume generated to the artificial lung, the total work of breathing, and the pressure-time product needed to trigger the ventilator. With NIV, the type of circuit setup had a significant impact on inspiratory flow preceding triggering of the ventilator (P < .0001), the inspiratory effort required to trigger the ventilator (P < .0001), the triggering delay (P < .0001), the maximal inspiratory pressure (P < .0001), the tidal volume (P = .0008), the work of breathing (P < .0001), and the pressure-time product needed to trigger the ventilator (P < .0001). Similar differences and consequences were seen with CPAP as well as with the addition of bacterial filters. Best performance was achieved with a dual-limb circuit with an oronasal mask. Worst performance was achieved with a dual-limb circuit with a helmet interface. Ventilator performance is significantly impacted by the circuit setup. A dual-limb circuit with oronasal mask should be used preferentially.

Sections du résumé

BACKGROUND
SARS-CoV-2 aerosolization during noninvasive positive-pressure ventilation may endanger health care professionals. Various circuit setups have been described to reduce virus aerosolization. However, these setups may alter ventilator performance.
RESEARCH QUESTION
What are the consequences of the various suggested circuit setups on ventilator efficacy during CPAP and noninvasive ventilation (NIV)?
STUDY DESIGN AND METHODS
Eight circuit setups were evaluated on a bench test model that consisted of a three-dimensional printed head and an artificial lung. Setups included a dual-limb circuit with an oronasal mask, a dual-limb circuit with a helmet interface, a single-limb circuit with a passive exhalation valve, three single-limb circuits with custom-made additional leaks, and two single-limb circuits with active exhalation valves. All setups were evaluated during NIV and CPAP. The following variables were recorded: the inspiratory flow preceding triggering of the ventilator, the inspiratory effort required to trigger the ventilator, the triggering delay, the maximal inspiratory pressure delivered by the ventilator, the tidal volume generated to the artificial lung, the total work of breathing, and the pressure-time product needed to trigger the ventilator.
RESULTS
With NIV, the type of circuit setup had a significant impact on inspiratory flow preceding triggering of the ventilator (P < .0001), the inspiratory effort required to trigger the ventilator (P < .0001), the triggering delay (P < .0001), the maximal inspiratory pressure (P < .0001), the tidal volume (P = .0008), the work of breathing (P < .0001), and the pressure-time product needed to trigger the ventilator (P < .0001). Similar differences and consequences were seen with CPAP as well as with the addition of bacterial filters. Best performance was achieved with a dual-limb circuit with an oronasal mask. Worst performance was achieved with a dual-limb circuit with a helmet interface.
INTERPRETATION
Ventilator performance is significantly impacted by the circuit setup. A dual-limb circuit with oronasal mask should be used preferentially.

Identifiants

pubmed: 33667491
pii: S0012-3692(21)00446-3
doi: 10.1016/j.chest.2021.02.047
pmc: PMC7921720
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

175-186

Investigateurs

Annalisa Carlucci (A)
Bruno Langevin (B)
Javier Sayas-Catalan (J)
Manuel Lujan-Torné (M)
Frederic Lofaso (F)
Claudio Rabec (C)
Joao Winck Carlo (JW)
Cristina Lamolda (C)

Commentaires et corrections

Type : CommentIn
Type : ErratumIn

Informations de copyright

Copyright © 2021 American College of Chest Physicians. Published by Elsevier Inc. All rights reserved.

Références

Am J Respir Crit Care Med. 2020 May 15;201(10):1299-1300
pubmed: 32228035
Respirology. 2019 Dec;24(12):1156-1164
pubmed: 30468277
Chest. 2005 May;127(5):1784-92
pubmed: 15888859
Eur Respir J. 2019 Apr 11;53(4):
pubmed: 30705129
Respir Med Res. 2020 Nov;78:100768
pubmed: 32707480
Chest. 2020 Sep;158(3):1046-1049
pubmed: 32247712
J Am Coll Emerg Physicians Open. 2020 May 29;:
pubmed: 32838373
Health Technol Assess. 2010 Oct;14(46):131-172
pubmed: 20923611
Chest. 2020 Nov;158(5):1992-2002
pubmed: 32681847
Crit Care Med. 2009 Jun;37(6):1921-8
pubmed: 19384209
Intensive Care Med. 2006 Oct;32(10):1515-22
pubmed: 16896854
Respir Care. 2013 Aug;58(8):1315-22
pubmed: 23232732
Thorax. 2019 Jul;74(7):715-717
pubmed: 31028239
Eur Respir J. 2015 Mar;45(3):691-9
pubmed: 25504992
Thorax. 2012 Jun;67(6):546-52
pubmed: 20971982
J Hosp Infect. 2020 Nov;106(3):570-576
pubmed: 32828864
Chest. 2020 Dec;158(6):2431-2435
pubmed: 32679237
Eur Respir J. 2020 Oct 15;56(4):
pubmed: 32747395
Eur Respir J. 2020 Aug 13;56(2):
pubmed: 32430410
Eur Respir J. 2020 Nov 5;56(5):
pubmed: 32747398
Eur Respir J. 2020 May 21;55(5):
pubmed: 32312865

Auteurs

Maxime Patout (M)

AP-HP, Groupe Hospitalier Universitaire APHP-Sorbonne Université, site Pitié-Salpêtrière, Service des Pathologies du Sommeil (Département R3S), F-75013 Paris, France; Sorbonne Université, INSERM, UMRS1158 Neurophysiologie Respiratoire Expérimentale et Clinique, F-75005 Paris, France; Respiratory Department, Avicenne Hospital, AP-HP, Bobigny, France; Normandie University, UNIRouen, EA3830-GRHV, Institute for Research and Innovation in Biomedicine (IRIB), Rouen, France. Electronic address: maxime.patout@aphp.fr.

Emeline Fresnel (E)

Normandie University, UNIRouen, EA3830-GRHV, Institute for Research and Innovation in Biomedicine (IRIB), Rouen, France; Kernel Biomedical, Bois-Guillaume, France.

Manuel Lujan (M)

Pneumology Department, Corporació Sanitaria Parc Taulí, Sabadell, Barcelona, Spain.

Claudio Rabec (C)

Pulmonary Department and Respiratory Critical Care Unit, University Hospital Dijon, Dijon, France; Fédération ANTADIR, Paris, France.

Annalisa Carlucci (A)

Pulmonary Rehabilitation, Istituti Clinici Scientifici Maugeri, Pavia, Italy; Department of Medicine, University of Insubria Varese, Como, Italy.

Léa Razakamanantsoa (L)

Normandie University, UNIRouen, EA3830-GRHV, Institute for Research and Innovation in Biomedicine (IRIB), Rouen, France.

Adrien Kerfourn (A)

Normandie University, UNIRouen, EA3830-GRHV, Institute for Research and Innovation in Biomedicine (IRIB), Rouen, France; Kernel Biomedical, Bois-Guillaume, France.

Hilario Nunes (H)

Respiratory Department, Avicenne Hospital, AP-HP, Bobigny, France; INSERM U1272, "Hypoxia and the Lung", Paris 13 University, Bobigny, France.

Yacine Tandjaoui-Lambiotte (Y)

INSERM U1272, "Hypoxia and the Lung", Paris 13 University, Bobigny, France; Intensive Care Unit, Avicenne Hospital, AP-HP, Bobigny, France.

Antoine Cuvelier (A)

Kernel Biomedical, Bois-Guillaume, France.

Jean-François Muir (JF)

Normandie University, UNIRouen, EA3830-GRHV, Institute for Research and Innovation in Biomedicine (IRIB), Rouen, France; Fédération ANTADIR, Paris, France.

Cristina Lalmoda (C)

Pneumology Department, Corporació Sanitaria Parc Taulí, Sabadell, Barcelona, Spain.

Bruno Langevin (B)

Réanimation, Pôle Soins Aigus, Centre Hospitalier Alès, Alès, France.

Javier Sayas (J)

Servicio de Neumología, Hospital Universitario 12 de Octubre, Madrid, Spain.

Jesus Gonzalez-Bermejo (J)

Sorbonne Université, INSERM, UMRS1158 Neurophysiologie Respiratoire Expérimentale et Clinique, F-75005 Paris, France; AP-HP, Groupe Hospitalier Universitaire APHP-Sorbonne Université, site Pitié-Salpêtrière, Service de Pneumologie, Médecine Intensive et Réanimation (Département R3S), F-75013 Paris, France.

Jean-Paul Janssens (JP)

Division of Pulmonary Diseases, Geneva University Hospitals (HUG), Geneva, Switzerland; Faculty of Medicine, University of Geneva, Geneva, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH